The leaders of the Early Detection In Syndromic Cancers consortium have clinical practices that currently follow over 600 adult and pediatric patients with LFS and represent major geographical areas in the United States. Each academic institution has built a biobank on existing cancer registries that have long-term independent funding.

Together, the osteosarcoma community has the power to move research forward. By generating the most comprehensive osteosarcoma database, we can accelerate research and the development of new therapies. Only you hold the key to unlock future discoveries.

The National Center for Advancing Translational Sciences (NCATS) — one of 27 Institutes and Centers at the National Institutes of Health (NIH) — was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.

PROXC is a multi-institutional effort which aims to facilitate the conduct of basic and translational research and provide clinical and therapeutic insight for pediatric cancers using patient-derived xenografts (PDXs) as validation tools. By federating PDX models developed at collaborating PROXC institutions, multi-directional sharing of models and associated clinical and molecular characterization data, and adoption of harmonized approaches for drug evaluation, PROXC seeks to develop and validate PDX models to accelerate the process of drug prioritization and enable substantive progress in the treatment of pediatric cancer.